MX2011012310A - Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen). - Google Patents

Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen).

Info

Publication number
MX2011012310A
MX2011012310A MX2011012310A MX2011012310A MX2011012310A MX 2011012310 A MX2011012310 A MX 2011012310A MX 2011012310 A MX2011012310 A MX 2011012310A MX 2011012310 A MX2011012310 A MX 2011012310A MX 2011012310 A MX2011012310 A MX 2011012310A
Authority
MX
Mexico
Prior art keywords
treatment
heart failure
ejection fraction
normal ejection
hfnef
Prior art date
Application number
MX2011012310A
Other languages
English (en)
Spanish (es)
Inventor
Michael Paul Frenneaux
Houman Ashrafian
Original Assignee
Heart Metabolics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heart Metabolics Ltd filed Critical Heart Metabolics Ltd
Publication of MX2011012310A publication Critical patent/MX2011012310A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MX2011012310A 2009-05-20 2009-05-20 Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen). MX2011012310A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2009/050539 WO2010133815A1 (en) 2009-05-20 2009-05-20 Treatment of heart failure with normal ejection fraction

Publications (1)

Publication Number Publication Date
MX2011012310A true MX2011012310A (es) 2012-04-11

Family

ID=41213178

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012310A MX2011012310A (es) 2009-05-20 2009-05-20 Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen).

Country Status (11)

Country Link
US (3) US8440697B2 (enExample)
EP (1) EP2432470A1 (enExample)
JP (1) JP2012527438A (enExample)
CN (1) CN102573844A (enExample)
AU (1) AU2009346606B2 (enExample)
BR (1) BRPI0924398A2 (enExample)
CA (1) CA2816448A1 (enExample)
IL (1) IL216362A0 (enExample)
MX (1) MX2011012310A (enExample)
WO (1) WO2010133815A1 (enExample)
ZA (1) ZA201109332B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405381D0 (en) 2004-03-10 2004-04-21 Univ Wales Medicine A method and means for treating heart failure
GB0908193D0 (en) 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
EP2432470A1 (en) 2009-05-20 2012-03-28 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction
AU2012297569B2 (en) 2011-08-16 2017-11-09 Baker Heart and Diabetes Institute Controlled-release formulation
EP2892529A4 (en) * 2012-09-05 2016-01-20 Adelaide Res &Innovation Pty Ltd USES OF (-) - PERHEXILINE
MX2017008248A (es) * 2014-12-22 2018-02-19 Cardiora Pty Ltd Metodo de tratamiento.
BR112019012214A8 (pt) 2016-12-15 2023-03-28 Baxter Int Sistema e método para monitorar e determinar parâmetros do paciente a partir de forma de onda venosa detectada
US11039754B2 (en) 2018-05-14 2021-06-22 Baxter International Inc. System and method for monitoring and determining patient parameters from sensed venous waveform

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN380695A0 (en) 1995-06-23 1995-07-20 Queen Elizabeth Hospital, The Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions
US20030162824A1 (en) * 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
GB0405381D0 (en) * 2004-03-10 2004-04-21 Univ Wales Medicine A method and means for treating heart failure
AU2005230811A1 (en) 2004-04-06 2005-10-20 Angiogenetics Sweden Ab Angiogenesis-affecting compounds and methods of use thereof
PL1959951T3 (pl) 2005-12-01 2010-06-30 Hoffmann La Roche Heteroarylo-podstawione pochodne piperydyny jako inhibitory l-cpt1
ITRM20060090A1 (it) 2006-02-22 2007-08-23 Sigma Tau Ind Farmaceuti Nuovi composti inibitori cpt a livello del snc come farmaci antidiabetici e o antiobesita
GB0723100D0 (en) * 2007-11-23 2008-01-02 Heart Metabolics Ltd Treatment of HFnEF
GB0908193D0 (en) * 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
EP2432470A1 (en) 2009-05-20 2012-03-28 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction
US20140019207A1 (en) 2012-07-11 2014-01-16 Sap Ag Interactive in-memory based sales forecasting
EP2892529A4 (en) 2012-09-05 2016-01-20 Adelaide Res &Innovation Pty Ltd USES OF (-) - PERHEXILINE
WO2015131231A1 (en) 2014-03-03 2015-09-11 Adelaide Research & Innovation Pty Ltd Methods for using (-)-perhexiline

Also Published As

Publication number Publication date
AU2009346606B2 (en) 2016-06-02
JP2012527438A (ja) 2012-11-08
US20100331364A1 (en) 2010-12-30
US9457017B2 (en) 2016-10-04
US8440697B2 (en) 2013-05-14
US20130210720A1 (en) 2013-08-15
CN102573844A (zh) 2012-07-11
CA2816448A1 (en) 2010-11-25
US20130210719A1 (en) 2013-08-15
WO2010133815A1 (en) 2010-11-25
BRPI0924398A2 (pt) 2019-09-24
ZA201109332B (en) 2012-08-29
AU2009346606A1 (en) 2012-01-19
IL216362A0 (en) 2012-01-31
US9468634B2 (en) 2016-10-18
EP2432470A1 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
MX338099B (es) Perhexilina para usarla en el tratamiento de miocardiopatía hipertrófica (hcm).
MX2011012310A (es) Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen).
WO2012062925A3 (en) Compounds and methods for treating pain
PH12013500919B1 (en) Vasoprotective and cardioprotective antidiabetic therapy
MA32389B1 (fr) Methode de traitement de la dyspnee associee a une insuffisance cardiaque aigue
WO2009045356A3 (en) Microrna compositions in the treatment of vegf-mediated disorders
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2012145651A3 (en) Compounds for the treatment of neuropsychiatric disorders
CO6630082A2 (es) Tratamiento de lupus nefritis usando laquinimod
MX2010002312A (es) Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
UA105029C2 (uk) ПОДВІЙНЕ НАЦІЛЮВАННЯ НА miR-208 І miR-499 У ЛІКУВАННІ ЗАХВОРЮВАНЬ СЕРЦЯ
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
UA99540C2 (ru) Замещенные мостиковым хиноксалином пиперидиновые соединения и их применение
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
MX2013008729A (es) Metodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales.
MX367811B (es) D-metadona para el tratamiento de síntomas psiquiátricos.
PH12013500231A1 (en) Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
EP2579863A4 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE MASTITIS
AR092103A1 (es) Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1)
EA201200428A1 (ru) Композиция и способ для лечения ожирения